Prostate Cancer
Conditions
Keywords
Castration-Resistant Prostate Cancer, Abiraterone acetate, Steroids Switch
Brief summary
Abiraterone acetate (AA) has shown a favourable impact in overall survival, administered with prednisone to decrease the adverse event related to CYP171A suppression. Our hypothesis is that the change of prednisone to dexamethasone in CRPC patients that progress biochemically to AA + prednisone can improve the number and the length of the responses, and also improve tolerance to treatment, decreasing the adverse events associated to a moderate dosage of steroids used chronically.
Detailed description
This phase II multicentric-study analyse the role of the steroid switch in patients receiving AA. Previous retrospective data (Lorente et al, BJC 2014) has shown that the change of prednisone by dexamethasone in CRPC patients treated with AA post-docetaxel leaded to durable biochemical responses in 40% of cases. Recently, superiority of dexamethasone over prednisone in PSA response has been reported by a phase II trial that included 82 chemotherapy-naive metastatic CRPC patients. In our study patients with biochemical and/or limited radiological progression to AA + prednisone are prospectively enrolled. The principal objective was to evaluate the percentage of PSA responses in clinically stable metastatic CRPC patients after at least 12 weeks of AA + prednisone. Secondary aims will include time to biochemical progression, time to first radiological progression, overall survival and the evaluation of the safety profile. Biochemical response was monitored with PSA determinations every 4 weeks, and defined as a ≥ 30% decline in PSA from baseline, confirmed with a second reading. PSA progression was evaluated according to PCWG2 criteria. Radiological response was re-evaluated every 12-16 weeks using bone and CT-scan according to RECIST v1.1 and PCWG2 criteria. Translational studies: archival tissue will be obtained from all patients, to perform PTEN and TMPRSS-ERG rearrangements evaluation. Plasma will be collected after AA + prednisone progression to study the androgen receptor status in plasma.
Interventions
DRUGSteroids switch
Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
Sponsors
Instituto de Investigacion Biomedica de Malaga
Fundación de investigación HM
Institute of Cancer Research, United Kingdom
University of Salamanca
Centro Nacional de Investigaciones Oncologicas CARLOS III
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
One-arm prospective
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Provision of signed informed consent 2. Patients must be 18 years old or older 3. Patients must have an acceptable performance status at study entry ECOG \<2, without prior deterioration due to disease clinical progression on abiraterone plus prednisone 4. Patients must have prior histological confirmation of prostate cancer diagnosis prior to study entry 5. Maintained castration status to LHRH analogs/antagonist or surgical castration with Testosterone blood levels \<0.5ng/mL should have been documented before the initiation of prior abiraterone plus prednisone treatment and confirmed again at study entry. Patients on LHRHa must be able to continue on them through the duration of the study. 6. Biochemical progression to abiraterone plus prednisone is required before study entry. This progression will be documented by a rising PSA value with an increase ≥25% and \>2ng/dL over nadir, and must be confirmed by a second determination at least 2 weeks later should be documented before study entry. 7. Candidates must be able to swallow pills and to continue with abiraterone acetate dose of 1000mg/24h and must not have any contraindication for dexamethasone use at 0.5 mg/24h. 8. Patients must be asymptomatic or do not have any symptomatic deterioration attributable to prostate cancer progression at study entry 9. Absence of significant radiological progression to abiraterone plus prednisone at study entry. Only those cases with limited progression will be eligible if: a) they have not developed any new visceral, nodal or other soft tissue metastases; b) their measurable target lesions on abiraterone plus prednisone according to RECIST 1.1 should have not increased more than 40% from baseline or from their best response on treatment measurements; and c) they must have \< 3 new bone metastasis on bone-scan from baseline according to PCWG2 10. Acceptable hematological, hepatic and renal functions, without contraindications for the administration of abiraterone: a) WBC count \>2000/mm\^3; b) Haemoglobin level \>10 g/dL; c) Platelets \>75000/mm\^3; AST/ALT \<2.5 times the upper normal limit; Total bilirubin \<1.5 times the upper normal limit; Creatinine value \<1.5 times the upper normal limit or creatinine clearance \>50 ml/min
Exclusion criteria
1. Any medical contraindication to continue on abiraterone acetate or to receive continuous daily low-dose of dexamethasone (0.5 mg/24h) 2. Any event which is considered clinical progression to abiraterone acetate by the attending physicians in the investigators team. 3. Any skeletal symptomatic event related to prostate cancer progression on abiraterone-acetate, except the administration of external beam radiotherapy due to bone-metastasis related-pain in a single area and which have resulted in a adequate symptom control for at least 4-weeks before study entry. 4. Radiological progression: a) New nodal, visceral or other soft tissue metastasis during the treatment with Abiraterone acetate and prednisone; b) increase of any target lesion \>40% according to RECIST v1.1 criteria; c) any known visceral, nodal or soft tissue metastasis localisation causing symptomatic progression, and d) ≥ 3 new bone metastasis on bone-scan during treatment with abiraterone plus prednisone. 5. Previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free, as well as subjects with a history of skin cancers (of non-melanoma type) or excised in situ carcinomas. 6. Any prior medical history, be they psychiatric or of any other character, which, according to the judgement of the investigator, might interfere with the subject's granting of informed consent or the safe execution of the procedures required in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the percentage of PSA response in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 12 months | Biochemical response will be defined as a ≥ 30% decline in PSA from starting AA + dexamethasone, confirmed with a second PSA reading at least 2 weeks apart. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To study time to biochemical (PSA) progression (>25% increase over PSA nadir value)in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 12 months | Time to biochemical progression is defined as the time from AA + dexamethasone starting data, to PSA progression according to PCWG2 criteria |
| To analyze the time to radiological progression in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 24 months | Time to radiological progression is defined as the time from AA+ dexamethasone starting date to the first occurrence of either progression by bone scan or progression by CT-scan (based on RECIST v1.1 and PCWG2 criteria), or death resulting from any cause. |
| To describe the activity of subsequent treatment-line after AA + dexamethasone in the study population. | 24 months | Subsequent therapies and their corresponding biochemical/radiological responses will be also recorded. |
| To report the safety profile in in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 24 months | Toxicity events will be collected prospectively in each visit according to CTCAE v4.0 criteria. |
| To explore potential androgen receptor pathway related circulating- and tissue-biomarkers in in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 24 months | Archival tissue for immunohistochemistry and FISH, and peripheral blood to extract plasma and perform AR amplification studies by ddPCR analysis and determination of AR Alternative splicing transcripts from exosomes. |
| To evaluate the overall survival in metastatic CRPC treated with AA + dexamethasone with biochemical and/or limited radiological progression. | 24 months | Overall survival is defined as the time from AA + dexamethasone starting date to the death or last follow up visit. |
Countries
Spain
Outcome results
None listed